The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The National Health Authority (NHA) aims to deliver 10 crore Ayushman Bharat cards in this financial year and extend free hospitalization benefits to 50 lakh people in a quarter
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing
Subscribe To Our Newsletter & Stay Updated
